PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000851148.10454.66 |
| _version_ | 1797285872330080256 |
|---|---|
| author | H. Wang Q. He R. Zhao L. Xie J. Ma C. Liu K. Lu H. Wei D. Liu L. Xing X. Deng Z. Sun X. Chu N. Gao Y. Zhong Y. Sun H. Zhang H. Zhang W. Xu Z. Li |
| author_facet | H. Wang Q. He R. Zhao L. Xie J. Ma C. Liu K. Lu H. Wei D. Liu L. Xing X. Deng Z. Sun X. Chu N. Gao Y. Zhong Y. Sun H. Zhang H. Zhang W. Xu Z. Li |
| author_sort | H. Wang |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:40Z |
| format | Article |
| id | doaj.art-773407d8b74743b08615b8fba8e2a211 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:40Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-773407d8b74743b08615b8fba8e2a2112024-03-02T07:47:32ZengWileyHemaSphere2572-92412022-06-0161950195110.1097/01.HS9.0000851148.10454.66202206003-01950PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIALH. Wang0Q. He1R. Zhao2L. Xie3J. Ma4C. Liu5K. Lu6H. Wei7D. Liu8L. Xing9X. Deng10Z. Sun11X. Chu12N. Gao13Y. Zhong14Y. Sun15H. Zhang16H. Zhang17W. Xu18Z. Li191 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinan2 Department of Hematology, Weihai Municipal Hospital, Weihai3 Department of Hematology, Jining First People’s Hospital, Jining4 Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai5 Department of Hematology, Binzhou Medical University Hospital, Binzhou6 Department of Hematology, Qingdao Municipal Hospital, Qingdao7 Department of Hematology, Weifang People’s Hospital, Weifang8 Department of Hematology, Linyi People’s Hospital, Linyi9 Department of Hematology, Affiliated Hospital of Jining Medical University, Jining10 Department of Hematology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China1 Department of Hematology, Shandong Cancer Hospital and Institute, Jinanhttp://journals.lww.com/10.1097/01.HS9.0000851148.10454.66 |
| spellingShingle | H. Wang Q. He R. Zhao L. Xie J. Ma C. Liu K. Lu H. Wei D. Liu L. Xing X. Deng Z. Sun X. Chu N. Gao Y. Zhong Y. Sun H. Zhang H. Zhang W. Xu Z. Li PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL HemaSphere |
| title | PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL |
| title_full | PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL |
| title_fullStr | PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL |
| title_full_unstemmed | PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL |
| title_short | PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL |
| title_sort | pb2079 interim report of bendamustine plus rituximab as first line induction therapy with or without lenalidomide maintenance therapy in chinese patients with inhl or emcl a multi center prospective trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000851148.10454.66 |
| work_keys_str_mv | AT hwang pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT qhe pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT rzhao pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT lxie pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT jma pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT cliu pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT klu pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT hwei pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT dliu pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT lxing pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT xdeng pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT zsun pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT xchu pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT ngao pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT yzhong pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT ysun pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT hzhang pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT hzhang pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT wxu pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial AT zli pb2079interimreportofbendamustineplusrituximabasfirstlineinductiontherapywithorwithoutlenalidomidemaintenancetherapyinchinesepatientswithinhloremclamulticenterprospectivetrial |